Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndromePUBT·8 hours agoTSHA-5.32%
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Buy" by BrokeragesMarket Beat·18 hours agoTSHA-5.32%STT+0.65%
Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?Simplywall·Jul 16 at 08:16 AMTSHA-5.32%
Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 millionPUBT·Jul 10 at 05:55 PMTSHA-5.32%
Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index DropSimplywall·Jul 10 at 08:17 AMTSHA-5.32%
Under the Radar: The Tech, Biotech, and Defense Shifts You MissedGlobal Report·Jul 8 at 10:32 PMVSTM-2.10%TBI+0.92%
Buy Rating Reaffirmed on Taysha’s Superior Trial Rigor and Safety Profile; $12 Price Target MaintainedTip Ranks·Jun 30 at 01:35 PMNGNE-1.88%TSHA-5.32%
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga_article·Jun 30 at 08:04 AMBCRX-0.43%EW-1.42%
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% UpsideTradingView·Jun 29 at 05:20 PMTSHA-5.32%
Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentationPUBT·Jun 29 at 08:56 AMTSHA-5.32%
Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific Meetingbenzinga_article·Jun 25 at 03:02 PMTSHA-5.32%
Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meetingPUBT·Jun 25 at 03:01 PMTSHA-5.32%
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Sessionbenzinga_article·Jun 25 at 07:08 AMFUL+1.05%TSHA-5.32%
